Commentary: The Weak Link In The Drug Safety Chain: Doctors

When Janssen Pharmaceutica announced on Mar. 23 that it would no longer sell Propulsid in the U.S., it took a swipe at the nation's doctors. They had been warned of the drug's risks, Janssen's press release said, but "some inappropriate use has continued." The implication: Doctors were prescribing it to patients they shouldn't be.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.